IL160093A0 - Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists - Google Patents

Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists

Info

Publication number
IL160093A0
IL160093A0 IL16009302A IL16009302A IL160093A0 IL 160093 A0 IL160093 A0 IL 160093A0 IL 16009302 A IL16009302 A IL 16009302A IL 16009302 A IL16009302 A IL 16009302A IL 160093 A0 IL160093 A0 IL 160093A0
Authority
IL
Israel
Prior art keywords
vla
antagonists
preparation
imidazolidine derivatives
novel imidazolidine
Prior art date
Application number
IL16009302A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL160093A0 publication Critical patent/IL160093A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16009302A 2001-08-01 2002-07-20 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists IL160093A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10137595A DE10137595A1 (de) 2001-08-01 2001-08-01 Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PCT/EP2002/008106 WO2003011288A1 (en) 2001-08-01 2002-07-20 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists

Publications (1)

Publication Number Publication Date
IL160093A0 true IL160093A0 (en) 2004-06-20

Family

ID=7693930

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16009302A IL160093A0 (en) 2001-08-01 2002-07-20 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists
IL160093A IL160093A (en) 2001-08-01 2004-01-27 Imidazolidine derivatives and pharmaceutical preparations comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160093A IL160093A (en) 2001-08-01 2004-01-27 Imidazolidine derivatives and pharmaceutical preparations comprising them

Country Status (30)

Country Link
US (1) US6962937B2 (xx)
EP (1) EP1414444B1 (xx)
JP (1) JP4676697B2 (xx)
KR (1) KR100910930B1 (xx)
CN (1) CN1537000B (xx)
AR (1) AR036349A1 (xx)
AT (1) ATE391504T1 (xx)
AU (1) AU2002328931B2 (xx)
BR (1) BR0211535A (xx)
CA (1) CA2455966C (xx)
CO (1) CO5550452A2 (xx)
DE (2) DE10137595A1 (xx)
DK (1) DK1414444T3 (xx)
ES (1) ES2301673T3 (xx)
HK (1) HK1066166A1 (xx)
HR (1) HRP20040108A2 (xx)
HU (1) HUP0401406A3 (xx)
IL (2) IL160093A0 (xx)
MX (1) MXPA04000041A (xx)
MY (1) MY133467A (xx)
NO (1) NO326696B1 (xx)
NZ (1) NZ530887A (xx)
PE (1) PE20030348A1 (xx)
PL (1) PL365396A1 (xx)
PT (1) PT1414444E (xx)
RS (1) RS6104A (xx)
RU (1) RU2318815C2 (xx)
TW (1) TWI325863B (xx)
WO (1) WO2003011288A1 (xx)
ZA (1) ZA200400194B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101011373B1 (ko) 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 항균작용을 갖는 ｎ-히드록시아미드 유도체
EP2093218A1 (en) * 2008-02-22 2009-08-26 Ruggero Fariello Arylalkyl substituted imidazolidinones
US20090275529A1 (en) * 2008-05-05 2009-11-05 Reiss Allison B Method for improving cardiovascular risk profile of cox inhibitors
DK3326645T3 (da) 2010-10-25 2020-06-15 Biogen Ma Inc Fremgangsmåder til bestemmelse af forskelle i alpha-4-integrinaktivitet ved korrelation af forskelle i svcam- og/eller smadcam-niveauer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (xx)
DE4009506A1 (de) * 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
CA2127462C (en) 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
WO1993015764A1 (en) 1992-02-12 1993-08-19 Biogen, Inc. Treatment for inflammatory bowel disease
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) * 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
DE4308034A1 (de) * 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JP4115517B2 (ja) 1994-01-25 2008-07-09 エラン ファーマシューティカルズ， インコーポレイテッド 白血球付着分子 ｖｌａ−４に対するヒト化抗体
WO1996000581A1 (en) 1994-06-29 1996-01-11 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) * 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
EP0796855B1 (de) * 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
CA2261848C (en) 1996-07-25 2006-10-24 Biogen, Inc. Cell adhesion inhibitors
DE19647382A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
TR200001179T2 (tr) 1997-10-31 2000-11-21 Aventis Pharma Ltd. Değiştirilmiş anilidler
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
NZ508033A (en) 1998-06-30 2002-12-20 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2000002903A1 (en) 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
CN1537000A (zh) 2004-10-13
US6962937B2 (en) 2005-11-08
NO326696B1 (no) 2009-02-02
US20030109497A1 (en) 2003-06-12
ATE391504T1 (de) 2008-04-15
IL160093A (en) 2009-05-04
HUP0401406A3 (en) 2004-11-29
TWI325863B (en) 2010-06-11
DE60226032T2 (de) 2009-05-20
MXPA04000041A (es) 2004-05-21
KR100910930B1 (ko) 2009-08-06
DE60226032D1 (de) 2008-05-21
HRP20040108A2 (en) 2004-06-30
JP4676697B2 (ja) 2011-04-27
RU2004105966A (ru) 2005-06-27
PL365396A1 (en) 2005-01-10
KR20040020076A (ko) 2004-03-06
RS6104A (xx) 2006-10-27
WO2003011288A1 (en) 2003-02-13
DK1414444T3 (da) 2008-08-04
EP1414444B1 (en) 2008-04-09
ES2301673T3 (es) 2008-07-01
CO5550452A2 (es) 2005-08-31
CA2455966A1 (en) 2003-02-13
RU2318815C2 (ru) 2008-03-10
DE10137595A1 (de) 2003-02-13
AU2002328931B2 (en) 2008-04-24
JP2005504033A (ja) 2005-02-10
PT1414444E (pt) 2008-05-27
MY133467A (en) 2007-11-30
AR036349A1 (es) 2004-09-01
CA2455966C (en) 2011-09-20
ZA200400194B (en) 2005-03-14
NO20040426L (no) 2004-03-26
NZ530887A (en) 2005-09-30
BR0211535A (pt) 2004-07-13
HK1066166A1 (en) 2005-03-18
HUP0401406A2 (hu) 2004-10-28
EP1414444A1 (en) 2004-05-06
CN1537000B (zh) 2010-05-12
PE20030348A1 (es) 2003-05-14

Similar Documents

Publication Publication Date Title
TWI371450B (en) Novel substituted dihydro 3-halo-1h-pyrazole-5-carboxylates,their preparation and use
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
HUP0500983A2 (en) Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
HUP0401461A3 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
HK1048999A1 (zh) 氮雜䓬吲衍生物，它們的製備和應用
PL351312A1 (en) New compounds, their preparation and use
HK1058361A1 (en) Urea derivatives as integrin alpha 4 antagonists
HK1081954A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
AU4667101A (en) Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
SI1268522T1 (sl) Novi antagonisti lhrh, njihova priprava in uporaba kot zdravila
IL135451A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
HUP0401092A3 (en) 5-halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidines as fungicides, preparation and use thereof
PL374858A1 (en) Novel arylimidazole derivatives, preparation and therapeutic uses thereof
IL160093A0 (en) Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists
PL362573A1 (en) Imidazolidine derivatives, their preparation, and their use as antinflamatory agent.
PL365342A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
HUP0202377A3 (en) N-substituted perhydrodiazines, preparation and use thereof
IL149993A0 (en) Novel heteroaryl derivatives, their preparation and use
IL135452A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
HK1065792A1 (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
SI1453783T1 (sl) Substituirani aril-cikloalkani in njihova uporaba kot sredstva proti raku
HUP0203455A3 (en) 2-arylquinoline derivatives, preparation and therautic use thereof
IL156593A0 (en) Mikanolide derivatives, their preparation and therapeutic uses
SI1383750T1 (sl) Derivati uree kot integrin alfa 4 antagonisti